---
title: "石藥集團附屬出售核心業務  作價 2.3 億人民幣"
description: "石藥集團公佈，附屬石藥創新向石藥控股集團出售非核心業務 - 北京國新匯金全數 30.0704% 股權，後者從事全媒體傳播業務平台的運營，現金代價 2.3 億人民幣。估計出售虧損約 1,500 萬人民幣。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/277049202.md"
published_at: "2026-02-26T13:28:46.000Z"
---

# 石藥集團附屬出售核心業務  作價 2.3 億人民幣

> 石藥集團公佈，附屬石藥創新向石藥控股集團出售非核心業務 - 北京國新匯金全數 30.0704% 股權，後者從事全媒體傳播業務平台的運營，現金代價 2.3 億人民幣。估計出售虧損約 1,500 萬人民幣。

石藥集團 (01093.HK) 公佈，附屬石藥創新向石藥控股集團出售非核心業務 - 北京國新匯金全數 30.0704% 股權，後者從事全媒體傳播業務平台的運營，現金代價 2.3 億人民幣。估計出售虧損約 1,500 萬人民幣。

### Related Stocks

- [510660.CN - 華夏醫藥ETF](https://longbridge.com/zh-HK/quote/510660.CN.md)
- [159849.CN - 招商中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/159849.CN.md)
- [159837.CN - 易方達中證生物科技主題ETF](https://longbridge.com/zh-HK/quote/159837.CN.md)
- [520880.CN - 華寶恆生港股通創新藥精選ETF](https://longbridge.com/zh-HK/quote/520880.CN.md)
- [159316.CN - 易方達恆生港股通創新藥ETF](https://longbridge.com/zh-HK/quote/159316.CN.md)
- [512010.CN - 易方達滬深300醫藥ETF](https://longbridge.com/zh-HK/quote/512010.CN.md)
- [588130.CN - 華夏上證科創板生物醫藥ETF](https://longbridge.com/zh-HK/quote/588130.CN.md)
- [520690.CN - 博時恆生港股通創新藥精選ETF](https://longbridge.com/zh-HK/quote/520690.CN.md)
- [513700.CN - 香港醫藥](https://longbridge.com/zh-HK/quote/513700.CN.md)
- [562050.CN - 華寶中證制藥ETF](https://longbridge.com/zh-HK/quote/562050.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | Shanghai Fosun Pharmaceutical Units Trial Nod for Lung Cancer Drug in China | [Link](https://longbridge.com/zh-HK/news/276886600.md) |
| China Medical System Gets China Acceptance for Atopic Dermatitis Drug | China Medical System Gets China Acceptance for Atopic Dermatitis Drug | [Link](https://longbridge.com/zh-HK/news/276718382.md) |
| Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | Shanghai Pharmaceuticals Obtains Singapore Marketing Approval for Anticoagulant Drug | [Link](https://longbridge.com/zh-HK/news/276822785.md) |
| China's Jiuyuan Genetic seeks approval for Wegovy biosimilar | Jiuyuan Genetic Biopharmaceutical has applied for approval to sell its biosimilar version of Wegovy in China, ahead of a | [Link](https://longbridge.com/zh-HK/news/276994337.md) |
| CStone Wins Second UK Approval for Lung Cancer Drug Sugemalimab | CStone Pharmaceuticals has received UK approval for its lung cancer drug, sugemalimab, as a monotherapy for adult patien | [Link](https://longbridge.com/zh-HK/news/276549711.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。